Please login to the form below

Not currently logged in
Email:
Password:

mutiple myeloma

This page shows the latest mutiple myeloma news and features for those working in and with pharma, biotech and healthcare.

Mixed cancer news from NICE

Mixed cancer news from NICE

Mixed cancer news from NICE. Agency backs Janssen’ s myeloma drug but denies Bayer’ s Xofigo in prostate cancer. ... The cost-effectiveness agency issued draft guidance giving the green light to Janssen's Velcade in the treatment of certain patients

Latest news

  • NICE denies early use of Janssen’s Velcade NICE denies early use of Janssen’s Velcade

    Janssen's Velcade is not a cost-effective use of NHS resources for the early treatment of multiple myeloma, according to new draft guidance from England's health guidance body. ... The drug is already recommended by NICE for use in combination with an

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics